ARTICLE | Clinical News
IR103: Phase II started
May 1, 2006 7:00 AM UTC
IMNR began a placebo-controlled, Remune-controlled, U.K. and Canadian Phase II trial in treatment-naïve patients. IR103 combines IMNR's HIV-1 immunogen with Amplivax, an immunostimulatory oligonucleot...